Sylvester Comprehensive Cancer Center, University of Miami | Strategic Alliance Partners

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Olaparib plus temozolomide was not superior to pazopanib or trabectedin for the treatment of patients with advanced uterine leiomyosarcoma.

Dara-KRd improved rates of MRD negativity compared with KRd alone in patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.

Mikkael A. Sekeres, MD, discusses the design of a study assessing the correlation between smoking intensity and genetic mutations in patients with MDS.

Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Mikkael A. Sekeres, MD, discusses questions that remain unanswered regarding the association between smoking and MDS development and progression.

Mikkael A. Sekeres, MD, discusses the implications of a study that found associations between smoking intensity and disease progression in MDS.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

Scientists from Sylvester Comprehensive Cancer Center have found that targeting ZNF638 can induce an antiviral response in glioblastoma.

Sylvester researchers recently published positive data on a new treatment regimen for patients with relapsed or refractory follicular lymphoma.

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.

Sangeetha Venugopal, MD, MS, discusses other notable myelofibrosis data from the 2024 ASH Annual Meeting.

Sangeetha Venugopal, MD, MS, discusses data from the BOREAS trial for navtemadlin in relapsed/refractory myelofibrosis.

Sangeetha Venugopal, MD, MS, discusses post hoc overall survival data for pacritinib in myelofibrosis.

Sangeetha Venugopal, MD, MS, discusses the relationship between thrombocytopenia and anemia on disease progression in myelofibrosis

Sangeetha Venugopal, MD, MS, discusses challenges with low-dose ruxolitinib in myelofibrosis.

The combination of bezuclastinib and sunitinib generated favorable efficacy outcomes vs historical data in patients with previously treated GIST.

Alvaro Alencar, MD, explains the rationale of a phase 1 trial investigating NX-5948, a BTK degrader, in chronic lymphocytic leukemia.

Lenalidomide plus luspatercept demonstrated safety, tolerability, and efficacy in patients with non-del(5q) myelodysplastic syndrome.

Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.

A person’s “biological age” may be a hidden factor in their risk of colorectal cancer before the age of 50.

Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.

Janaki Neela Sharma, MD, discusses how data from EV-302 further defined the role of frontline enfortumab vedotin plus pembrolizumab in bladder cancer.

Justin M. Watts, MD, discusses the potential advantages of the oral small molecule BET inhibitor INCB057643 in advanced myelofibrosis.

Cindy M. Pabon, MD, highlights key findings and the clinical implications of 3 trials addressing questions in gastric and gastroesophageal cancer.

Janaki Neela Sharma, MD, discusses the implications of treatment advances in the front line for patients with advanced bladder cancer.

Janaki Neela Sharma, MD, discusses CheckMate 901, and where nivolumab plus chemotherapy fits into the advanced urothelial cancer treatment paradigm.

Janaki Neela Sharma, MD, discusses takeaways from the Sylvester Comprehensive Cancer Center 2024 Annual Oncology Update.